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We report 2 cases of leishmaniasis in patients with au-
toimmune rheumatic diseases in Greece. To assess trends 
in  leishmaniasis  reporting  in  this  patient  population,  we 
searched the literature for similar reports from Europe. Re-
ports increased during 2004–2008, especially for patients 
treated with anti–tumor necrosis factor agents.
W
e report 2 new cases of leishmaniasis involving pa-
tients with autoimmune rheumatic diseases who re-
ceived anti–tumor necrosis factor (anti-TNF) agents. We 
also reviewed all similar cases from Europe reported in the 
literature, and we discuss the implications of leishmaniasis 
in the setting of anti-TNF therapy, which is associated with 
increased risk for opportunistic infections (1).
The Study
Patient 1, a 55-year-old man who had received a diag-
nosis of ankylosing spondylitis 7 years previously, was ad-
mitted to Laikon Hosptal, Athens, Greece, in May 2005 for 
evaluation of encrusted vesicular lesions on the face. The 
lesions were painless but mildly pruritic. The patient had 
been receiving nonsteroidal antiinflammatory agents until 
12 months before admission, when his medications were 
changed to infliximab (3 mg/kg) plus methotrexate (10 mg 
weekly) because of his deteriorating clinical condition. He 
was living in a leishmaniasis-endemic area in Athens, had 
no pets in his house, and had no history of recent travel 
abroad. The central scale was removed from one of the le-
sions, and scrapings from the base of the lesion were stained 
with Giemsa stain, which showed intracellular amastigotes 
with peripheral nuclei and rod-shaped kinetoplasts. Results 
of indirect immunoflorescent antibody (IFA) testing were 
positive for Leishmania parasites (titer 6,400). Infliximab 
and methotrexate therapy was discontinued, and treatment 
with liposomal amphotericin B was started at a dose of 3 
mg/kg, for days 1 to 5, and 2 additional doses (3 mg/kg) 
on days 14 and 21. Eighteen months later, treatment with 
etanercept was begun due to the patient’s severe spondy-
loarthritis; 2 years after the new anti-TNF treatment, he is 
well, with no signs or symptoms of leishmaniasis.
Patient 2, a 71-year-old woman who had giant cell ar-
teritis, was admitted to the Euroclinic Hospital, Athens, in 
May 2005 with a high fever and fatigue. The patient had 
been treated with infliximab (0.25 mg/kg) and variable dos-
es of methylprednisolone for the previous 2 years. Metho-
trexate (10 mg/week) was added 1 year before admission. 
She was also living in an Athens suburb, which is leishma-
niasis-endemic, and had 4 dogs. Laboratory tests showed a 
high level of C-reactive protein (163 mg/L, reference range 
0–6 mg/L), high erythrocyte sedimentation rate (77 mm/h), 
pancytopenia (hemoglobin level 12.5 g/dL, leukocyte count 
3,300/mm3, platelet count 122,000/ mm3), and diffuse hy-
perglobulinemia.  The  examination  of  Giemsa-stained 
smears from bone marrow aspirate demonstrated abundant 
Leishmania parasites, and IFA was marginally positive for 
Leishmania antibodies (titer 400). PCR was positive for the 
detection of the Leishmania genome in peripheral blood. 
Infliximab and methotrexate treatment was discontinued, 
and  treatment  with  intravenous  liposomal  amphotericin 
B was started at a dose of 3 mg/kg for 5 days. Two days 
later, the fever subsided, and within the next few days, the 
patient recovered from pancytopenia, while the inflamma-
tory markers showed a gradual decrease. She received 2 
additional doses of liposomal amphotericin B (3 mg/kg) on 
days 7 and 14, and by that time, she exhibited no signs or 
symptoms of visceral leishmaniasis.
We  then  searched  Medline,  EMBASE,  and  Current 
Contents databases for all reports on leishmaniasis in Eu-
rope and the Mediterranean area among patients with auto-
immune rheumatic diseases, which are often treated with 
anti-TNF agents. In our search strategy, we used medical 
subject heading terms and text words, including rheuma-
toid arthritis, juvenile rheumatoid arthritis, Still’s disease, 
seronegative arthritis, psoriatic arthritis, Behçet’s disease, 
ankylosing spondylitis, reactive arthritis, vasculitis, giant 
cell  arteritis,  Wegener’s  granulomatosis  (ANCA  [anti-
neutrophil  cytoplasmic  antibody]–associated  vasculitis), 
panarteritis nodosa, leishmaniasis, Leishmania, and anti-
TNF. We searched the reference list of each resulting re-
port for additional publications. We used no language or 
time restrictions.
All retrieved articles were case reports. We found 13 
additional cases of leishmaniasis in patients with autoim-
mune  rheumatic  diseases  (2–14),  all  published  after  the 
introduction of anti-TNF agents in 1998 (Table). All 15 
patients (including our 2 patients) were treated in the past 
or at the time of the diagnosis of leishmaniasis with >1 
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standard immunosuppressive agents, including corticoster-
oids (11/14 [78.5%]) patients for whom treatment details 
were reported), methotrexate (9/14 [64.3%]), cyclosporine 
(3/14  [21.4%]),  cyclophosphamide  (3/14  [21.4%]),  aza-
thioprine (2/14 [14.3]), and chlorambucil (1/14 [7.1%]). 
Seven (46.6%) patients received an anti-TNF agent along 
with standard immunosuppressive agents. Two of the 15 
reported  patients  had  been  treated  with  a  recombinant 
interleukin–1 receptor antagonist (anakinra; Amgen Inc., 
Thousand Oaks, CA, USA) (5,13). In most of the patients, 
visceral  leishmaniasis  developed  (13  patients,  86.6%), 
while cutaneous leishmaniasis developed in 2 patients (1 
was receiving an anti-TNF agent). All patients were living 
in leishmaniasis-endemic areas of Europe (Figure).
The  anti-TNF  agents  were  introduced  into  clinical 
practice in 1998, and the first case of leishmaniasis associ-
ated with anti-TNF blockade occurred in 2001 (4). During 
the 6-year period (1998–2003), a total of 6 reports were 
made of leishmaniasis in patients with rheumatic diseases; 
1 (16.6%) occurred in a patient treated with an anti-TNF 
agent. During the ensuing 5 years (2004–2008), 9 cases of 
leishmaniasis were reported, 6 (66.6%) in patients receiv-
ing anti-TNF agents.
The  median  duration  of  previous  immunosuppres-
sive therapy, before the diagnosis of leishmaniasis, was 60 
months (range 2–360 months) for all 15 patients (Τable). 
For the 7 patients who received anti-TNF agents, the me-
dian duration of anti-TNF treatment was 18 months (range 
9–60 months). Six of these 7 patients were receiving anti-
TNF agents when symptoms and signs of leishmaniasis 
occurred. In 1 patient (5), biologic treatments had been 
discontinued 6 months before the diagnosis of leishmania-
sis (Table). Only 1 patient had been tested for antibodies 
against Leishmania spp. before immunosuppressive thera-
py was begun, and the results were negative (6). Therefore, 
this is the only case with compelling evidence that leish-
maniasis was a primary infection and not reactivation of a 
latent infection.
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Table. Detailed characteristics of 15 patients with autoimmune rheumatic disorders in whom leishmaniasis developed, Europe*  
Anti-TNF treatment  Other immunosuppressive treatments 
Patient
no. Country 
Age,
y/sex Disease Agent
Duration,
mo Agent(s)
Duration,
mo
Form of 
Leishmania
infection Ref.
1 France 66/M ANCA-
associated
vasculitis
NA NA Cyclophosphamide, 
methotrexate, 
corticosteroids
120 Visceral (7)
2 Israel 56/M Rheumatoid
arthritis
NA NA Methotrexate, 
corticosteroids
120 Cutaneous (8)
3 Italy 35/M Behçet
disease
NA NA Chlorambucil, 
corticosteroids
36 Visceral (9)
4 Spain 50/M Rheumatoid
arthritis
NA NA Methotrexate, 
corticosteroids
120 Visceral (10)
5 Italy 60/M Polyarteritis 
nodosa
NA NA Cyclophosphamide, 
corticosteroids
2 Visceral (11)
6 Spain 55/M Psoriatic
arthritis
Infliximab 9 No details given 300 Visceral (2)
7 Italy 76/M ANCA-
associated
vasculitis
NA NA Cyclophosphamide, 
corticosteroids
36 Visceral (12)
8 France 53/F Rheumatoid
arthritis
Infliximab 12 Azathioprine,
corticosteroids
12 Visceral (3)
9 Italy 69/F Rheumatoid
arthritis
Adalimumab 25 Methotrexate, 
corticosteroids
360 Visceral (4)
10 Greece 60/F Rheumatoid
arthritis
Etanercept 18† Cyclosporine, 
corticosteroids, anakinra
96 Visceral (5)
11 France 9/F Juvenile
rheumatoid
arthritis
NA NA Cyclosporine, 
methotrexate, 
corticosteroids, anakinra
60 Visceral (13)
12 Greece 45/M Psoriatic
arthritis
Infliximab 60 Methotrexate, 
corticosteroids
60 Visceral (6)
13 Greece 65/F Rheumatoid
arthritis
NA NA Methotrexate 96 Visceral (14)
14 Greece 71/F Giant cell 
arteritis
Infliximab 24 Methotrexate, 
corticosteroids
24 Visceral This 
study
15 Greece 55/M Ankylosing 
spondylitis
Infliximab 12 Methotrexate 12 Cutaneous This 
study
*TNF, tumor necrosis factor; Ref., reference; ANCA, anti-neutrophil cytoplasmic antibody; NA, not applicable. 
†All biologic treatments had been terminated 6 mo before leishmaniasis occurred. Conclusions
Our data suggest that the introduction of TNF block-
ade into the clinical practice is associated with increasing 
reports of leishmaniasis in patients with autoimmune rheu-
matic diseases who live in leishmaniasis-endemic areas of 
Europe. Notably, in most reported cases, patients had not 
received anti-TNF agents but other immunosuppressants. 
However, all cases of leishmaniasis in patients with auto-
immune rheumatic diseases were reported after 1998, the 
year of introduction of anti-TNF agents, and most (9/15) of 
the reported leishmaniasis cases occurred during the past 5 
years (2004–2008), mainly among patients receiving anti-
TNF agents (6 of the 9 patients with leishmaniasis; 66.6%). 
This increase coincides with the increasing use of anti-TNF 
agents  during  the  same  period,  as  prescription  practice 
started changing toward treating patients with lower disease 
activity (15). Another indirect piece of evidence that TNF 
blockade may increase the risk for leishmaniasis is that the 
median duration of previous anti-TNF treatment before the 
diagnosis of leishmaniasis was significantly shorter than 
the median duration of immunosuppressive therapy for all 
15 patients (18 vs. 60 months).
Our report has limitations. It is unclear for all cases 
(with 1 exception) presented in this article whether leish-
maniasis was primary infection or reactivation of latent 
disease. We cannot also exclude the possibility that the 
concomitant, long-term use of other immunosuppressants, 
and not the anti-TNF agents per se, played a crucial role 
in the development of leishmaniasis. Different prescribing 
patterns of anti-TNF agents might influence the number of 
cases reported from each disease-endemic European coun-
try. However, the small number of reported cases and the 
lack of data on differences in the anti-TNF prescribing poli-
cies do not allow any conclusions to be reached. Finally, 
due to underreporting, the reported cases may underesti-
mate the real incidence of leishmaniasis among patients 
with autoimmune rheumatic diseases.
Prospective studies to estimate the incidence of the 
disease, the impact of risk factors and the need for sero-
logic screening for leishmaniasis before initiation of anti-
TNF  agents  or  any  other  immunosuppressive  treatment 
are  clearly  needed.  This  is  particularly  important  since 
currently only a few patients with autoimmune rheumatic 
diseases receive anti-TNF agents (15). Therefore, the use 
of anti-TNF treatment is likely going to increase, possibly 
causing a parallel increase in opportunistic infections such 
as leishmaniasis.
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